Intervention Review

You have free access to this content

Antibiotics for preterm rupture of membranes

  1. Sara Kenyon1,*,
  2. Michel Boulvain2,
  3. James P Neilson3

Editorial Group: Cochrane Pregnancy and Childbirth Group

Published Online: 2 DEC 2013

Assessed as up-to-date: 26 NOV 2013

DOI: 10.1002/14651858.CD001058.pub3


How to Cite

Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD001058. DOI: 10.1002/14651858.CD001058.pub3.

Author Information

  1. 1

    University of Birmingham, School of Health and Population Sciences, Edgbaston, UK

  2. 2

    Maternité Hôpitaux Universitaires de Genève, Département de Gynécologie et d'Obstétrique, Unité de Développement en Obstétrique, Genève 14, Switzerland

  3. 3

    The University of Liverpool, Department of Women's and Children's Health, Liverpool, UK

*Sara Kenyon, School of Health and Population Sciences, University of Birmingham, Public Health Building, Edgbaston, B15 2TT, UK. s.kenyon@bham.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 2 DEC 2013

SEARCH

[Figure 1]
Figure 1. Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
[Figure 2]
Figure 2. Funnel plot of comparison: 1 Any antibiotic versus placebo, outcome: 1.3 Perinatal death/death before discharge.
[Figure 3]
Figure 3. Funnel plot of comparison: 1 Any antibiotic versus placebo, outcome: 1.4 Neonatal infection including pneumonia.
[Figure 4]
Figure 4. Funnel plot of comparison: 1 Any antibiotic versus placebo, outcome: 1.5 Neonatal necrotising enterocolitis.
[Figure 5]
Figure 5. Funnel plot of comparison: 1 Any antibiotic versus placebo, outcome: 1.7 Major cerebral abnormality on ultrasound before discharge.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Any antibiotic versus placebo, Outcome 1 Maternal death.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Any antibiotic versus placebo, Outcome 3 Perinatal death/death before discharge.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Any antibiotic versus placebo, Outcome 4 Neonatal infection including pneumonia.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Any antibiotic versus placebo, Outcome 5 Neonatal necrotising enterocolitis.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Any antibiotic versus placebo, Outcome 6 Oxygen treatment > 36 weeks' postconceptual age.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Any antibiotic versus placebo, Outcome 7 Major cerebral abnormality on ultrasound before discharge.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Any antibiotic versus placebo, Outcome 8 Birth before 37 weeks' gestation.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Any antibiotic versus placebo, Outcome 9 Major adverse drug reaction.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Any antibiotic versus placebo, Outcome 10 Maternal infection after delivery prior to discharge.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Any antibiotic versus placebo, Outcome 11 Chorioamnionitis.
[Analysis 1.12]
Analysis 1.12. Comparison 1 Any antibiotic versus placebo, Outcome 12 Caesarean section.
[Analysis 1.15]
Analysis 1.15. Comparison 1 Any antibiotic versus placebo, Outcome 15 Birth within 48 hours of randomisation.
[Analysis 1.16]
Analysis 1.16. Comparison 1 Any antibiotic versus placebo, Outcome 16 Birth within 7 days of randomisation.
[Analysis 1.17]
Analysis 1.17. Comparison 1 Any antibiotic versus placebo, Outcome 17 Birthweight.
[Analysis 1.18]
Analysis 1.18. Comparison 1 Any antibiotic versus placebo, Outcome 18 Birthweight < 2500 g.
[Analysis 1.19]
Analysis 1.19. Comparison 1 Any antibiotic versus placebo, Outcome 19 Neonatal intensive care.
[Analysis 1.20]
Analysis 1.20. Comparison 1 Any antibiotic versus placebo, Outcome 20 Days in neonatal intensive care unit.
[Analysis 1.21]
Analysis 1.21. Comparison 1 Any antibiotic versus placebo, Outcome 21 Positive neonatal blood culture.
[Analysis 1.22]
Analysis 1.22. Comparison 1 Any antibiotic versus placebo, Outcome 22 Neonatal respiratory distress syndrome.
[Analysis 1.23]
Analysis 1.23. Comparison 1 Any antibiotic versus placebo, Outcome 23 Treatment with surfactant.
[Analysis 1.24]
Analysis 1.24. Comparison 1 Any antibiotic versus placebo, Outcome 24 Number of babies requiring ventilation.
[Analysis 1.25]
Analysis 1.25. Comparison 1 Any antibiotic versus placebo, Outcome 25 Number of babies requiring oxygen therapy.
[Analysis 1.26]
Analysis 1.26. Comparison 1 Any antibiotic versus placebo, Outcome 26 Neonatal oxygenation > 28 days.
[Analysis 1.27]
Analysis 1.27. Comparison 1 Any antibiotic versus placebo, Outcome 27 Neonatal encephalopathy.
[Analysis 1.28]
Analysis 1.28. Comparison 1 Any antibiotic versus placebo, Outcome 28 Serious childhood disability at 7 years.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 3 Major adverse drug reaction.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 4 Maternal infection after delivery prior to discharge.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 6 Caesarean section.
[Analysis 2.9]
Analysis 2.9. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 9 Birth within 48 hours of randomisation.
[Analysis 2.10]
Analysis 2.10. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 10 Birth within 7 days of randomisation.
[Analysis 2.11]
Analysis 2.11. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 11 Birth before 37 weeks' gestation.
[Analysis 2.12]
Analysis 2.12. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 12 Birthweight.
[Analysis 2.13]
Analysis 2.13. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 13 Birthweight < 2500 g.
[Analysis 2.14]
Analysis 2.14. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 14 Neonatal intensive care.
[Analysis 2.17]
Analysis 2.17. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 17 Positive neonatal blood culture.
[Analysis 2.18]
Analysis 2.18. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 18 Neonatal necrotising enterocolitis.
[Analysis 2.19]
Analysis 2.19. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 19 Neonatal respiratory distress syndrome.
[Analysis 2.20]
Analysis 2.20. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 20 Treatment with surfactant.
[Analysis 2.21]
Analysis 2.21. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 21 Number of babies requiring ventilation.
[Analysis 2.22]
Analysis 2.22. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 22 Number of babies requiring oxygen therapy.
[Analysis 2.23]
Analysis 2.23. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 23 Neonatal oxygenation > 28 days.
[Analysis 2.24]
Analysis 2.24. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 24 Oxygen treatment > 36 weeks' postconceptual age.
[Analysis 2.26]
Analysis 2.26. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 26 Major cerebral abnormality on ultrasound before discharge.
[Analysis 2.27]
Analysis 2.27. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 27 Perinatal death/death before discharge.
[Analysis 2.28]
Analysis 2.28. Comparison 2 Erythromycin versus co-amoxiclav, Outcome 28 Serious childhood disability at 7 years.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Antibiotics versus no antibiotic, Outcome 1 Perinatal death/death before discharge.
[Analysis 5.4]
Analysis 5.4. Comparison 5 3 versus 7 day ampicillin regimens, Outcome 4 Maternal infection after delivery prior to discharge.
[Analysis 5.5]
Analysis 5.5. Comparison 5 3 versus 7 day ampicillin regimens, Outcome 5 Chorioamnionitis.
[Analysis 5.6]
Analysis 5.6. Comparison 5 3 versus 7 day ampicillin regimens, Outcome 6 Caesarean section.
[Analysis 5.9]
Analysis 5.9. Comparison 5 3 versus 7 day ampicillin regimens, Outcome 9 Birth within 48 hours of randomisation.
[Analysis 5.10]
Analysis 5.10. Comparison 5 3 versus 7 day ampicillin regimens, Outcome 10 Birth within 7 days of randomisation.
[Analysis 5.14]
Analysis 5.14. Comparison 5 3 versus 7 day ampicillin regimens, Outcome 14 Neonatal intensive care.
[Analysis 5.18]
Analysis 5.18. Comparison 5 3 versus 7 day ampicillin regimens, Outcome 18 Neonatal necrotising enterocolitis.
[Analysis 5.19]
Analysis 5.19. Comparison 5 3 versus 7 day ampicillin regimens, Outcome 19 Neonatal respiratory distress syndrome.
[Analysis 5.26]
Analysis 5.26. Comparison 5 3 versus 7 day ampicillin regimens, Outcome 26 Neonatal intraventricular haemorrhage.
[Analysis 5.27]
Analysis 5.27. Comparison 5 3 versus 7 day ampicillin regimens, Outcome 27 Perinatal death/death before discharge.